Despite the differences in severity of these two murine lupus-prone models, both strains proportionally benefited from Hybri and CYP therapies, as demonstrated by the reduction in proteinuria, renal histological damage, and serological activity. This evidence concerns the gene PPIG and systemic lupus erythematosus.